nabu.science
MethodologyAboutContact

 

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Impact Profile
Free · About 5 minutes
Report #NBU-BD5ED35C·Framework v5.8·Pipeline v0.4·Evaluated 19 Aug 2026·OECD: 3.2 Clinical medicine·Subfield: Molecular Biology·Basis: Full text·Type: Laboratory experiment

Cell-specific Activation of the Nrf2 Antioxidant Pathway Increases Mucosal Inflammation in Acute but Not in Chronic Colitis

Alexandra Gerstgrasser et al.Alexandra Gerstgrasser, Hassan Melhem, Irina Leonardi et al.·2016·10.1093/ecco-jcc/jjw172 ↗

Primary claim

Expression of caNrf2 either in epithelial cells or myeloid cells resulted in aggravation of DSS-induced acute colitis.

Well-supported · two cell-specific models showed concordant worsening across complementary acute-colitis outcomes
In brief

Cell-specific constitutive Nrf2 activation convincingly aggravates acute murine colitis, but the underpowered chronic model limits conclusions about disease-stage dependence.

ReliabilityNo concerns4 of 4 checks completeSee what was checked ↓
Possible — the claim's weakest requirement is that the effect exists at all. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.
Abstract

BACKGROUND AND AIMS: The transcription factor Nrf2 is a major modulator of the cellular antioxidant response. Oxidative burst of infiltrating macrophages leads to a massive production of reactive oxygen species in inflamed tissue of inflammatory bowel disease patients. This oxidative burst contributes to tissue destruction and epithelial permeability, but it is also an essential part of the antibacterial defence. We therefore investigated the impact of the Nrf2 orchestrated antioxidant response in both acute and chronic intestinal inflammation. METHODS: To study the role of Nrf2 overexpression in mucosal inflammation, we used transgenic mice conditionally expressing a constitutively active form of Nrf2 [caNrf2] either in epithelial cells or in the myeloid cell lineage. Acute colitis was induced by dextran sulphate sodium [DSS] in transgenic and control animals, and changes in gene expression were evaluated by genome-wide expression studies. Long-term effects of Nrf2 activation were studied in mice with an IL-10-/- background. RESULTS: Expression of caNrf2 either in epithelial cells or myeloid cells resulted in aggravation of DSS-induced acute colitis. Aggravation of inflammation by caNrf2 was not observed in the IL-10-/- model of spontaneous chronic colitis, where even a trend towards reduced prolapse rate was observed. CONCLUSIONS: Our findings show that a well-balanced redox homeostasis is as important in epithelial cells as in myeloid cells during induction of colitis. Aggravation of acute DSS colitis in response to constitutive Nrf2 expression emphasises the importance of tight regulation of Nrf2 during the onset of intestinal inflammation.

Key Claims

Primary finding · Well-supported

Expression of caNrf2 either in epithelial cells or myeloid cells resulted in aggravation of DSS-induced acute colitis.

Possible — the claim's weakest requirement is that the effect exists at all. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.

two cell-specific models showed concordant worsening across complementary acute-colitis outcomes

Abstract; Results, Figures 1–2
Quote verified
Secondary · Tentative

Aggravation of inflammation by caNrf2 was not observed in the IL-10-/- model of spontaneous chronic colitis, where even a trend towards reduced prolapse rate was observed.

the chronic design relies on underpowered null comparisons and non-significant sex-stratified trends

Abstract; Results, Figures 5–6
Quote verified
Secondary · Supported

Our findings show that a well balanced redox homeostasis is equally important in epithelial cells as well as myeloid cells during induction of colitis.

parallel acute phenotypes support the interpretation, although the redox mechanism remains unresolved

Abstract, Conclusions; Discussion, p. 21
Quote verified
Secondary · Supported

Aggravation of acute DSS colitis in response to constitutive Nrf2 expression emphasizes the importance of tight regulation of Nrf2 during the onset of intestinal inflammation.

acute aggravation is consistent, but the experiment does not directly identify the optimal regulatory range

Abstract, Conclusions
Quote verified

Derived from the full evaluation — not a separate score.

Strengths · Limitations

Strengths

#contribution

Convergent acute findings across cell lineages

Constitutive Nrf2 activation increased acute DSS disease severity in both epithelial and myeloid models, with significant effects across complementary outcomes such as weight loss, colon length, and histology.

↳ Results, Figures 1–2

#methodological rigour

Transparent multi-outcome experimental reporting

The study reports significant, null, and trend-level outcomes, including unchanged colonoscopy and MPO measurements rather than presenting only supportive endpoints. Endoscopic scoring was performed by a blinded independent investigator.

↳ Materials and Methods; Results, Figures 1–2

#positioning

Direct engagement with contradictory evidence

The Discussion addresses Nrf2 knockout studies, sulforaphane and gallic-acid experiments, and divergent tissue-specific gain-of-function findings. It also distinguishes intermittent pharmacological activation from constitutive genetic activation.

↳ Discussion, pp. 21–23

Limitations

#methodological rigour

Multiplicity weakens secondary molecular findings

Numerous cytokine and gene-expression comparisons are reported across genotypes, treatments, lineages, and sexes without a stated multiplicity correction outside the RNA-sequencing analysis. This raises false-positive risk, particularly for Figure 7.

↳ Statistical Analysis; Results, Figures 3 and 7

#contribution

Chronic comparison is statistically underpowered

The chronic model relies heavily on non-significant prolapse trends and sex-stratified analyses with n=4–8 for cytokine measurements. These data do not establish the acute-versus-chronic distinction with the same certainty as the acute findings.

↳ Results, Figures 5–7

#application pathway

Therapeutic inference exceeds intervention tested

The proposed distinction between remission maintenance and acute-flare therapy extrapolates from constitutive genetic activation in mice to pharmacological treatment in patients. The article itself notes that transient drug activation may behave differently.

↳ Discussion, pp. 21–26

Does this match your read? Add your assessment ↓

Nabu Commentary

The strongest evidence comes from Figures 1 and 2, where two cell-specific transgenic models show concordant worsening of acute DSS colitis across complementary outcomes. The methods are competent and null endpoints are reported transparently, but multiplicity and small secondary-analysis samples constrain mechanistic certainty. Figures 5–7 provide a useful chronic comparison, although underpowered null findings and sex-stratified trends cannot establish stage dependence as firmly as the acute experiments. The Discussion is well situated in contradictory Nrf2 literature, but its therapeutic timing proposal remains several translational steps beyond the intervention tested.

Evaluate another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Evidence Score

Out of 5
012345
3.5±0.2

Contribution
3.6

The study meaningfully extends prior loss-of-function work by showing that constitutive Nrf2 activation aggravates acute DSS colitis in two cell lineages. The acute-versus-chronic contrast is informative, although the chronic evidence is largely null or trend-level.

Abstract; Results, Figures 1–2 and 5–6

Expression of caNrf2 either in epithelial cells or myeloid cells resulted in aggravation of DSS-induced acute colitis.

Methodological Rigour
3.5

Two cell-specific transgenic systems, littermate controls, repeated acute experiments, multiple outcomes, and blinded endoscopy provide a competent design. Small chronic and RNA-sequencing samples, incomplete blinding, and uncorrected multiplicity in secondary analyses limit certainty.

Materials and Methods; Results, Figures 1–3 and 7

Results represent two independent acute colitis experiments with a total of n = 14 per group.

Reporting
3.8

The paper progresses coherently from the acute models to the chronic model and mechanistic follow-up, while distinguishing significant findings from trends. Translational language remains hedged, although several non-significant trends receive notable narrative weight.

Abstract; Results; Discussion, pp. 20–26

where even a trend towards reduced prolapse rate was observed

Positioning
3.5

The Discussion directly engages knockout, pharmacological-activation, and tissue-specific gain-of-function evidence and explains why constitutive activation may differ. Power limitations in the sex-stratified chronic analyses are not traced through the corresponding sex-specific interpretations.

Discussion, pp. 21–26; Results, Figure 7

This lower expression of pro-inflammatory cytokines corresponds well to the observed amelioration of colitis

Reliability

No concerns4 of 4 checks


Internal CoherenceClean

The numerical findings, methods, and central conclusions are internally coherent, and null outcomes are reported alongside significant results. A single IL-20 reference in the chronic-colitis section is an evident typographical error for IL-10.

Research ConductClean

Animal ethics authorization is declared and the RNA-sequencing data are assigned a GEO accession. No conflict-of-interest disclosure is visible in the supplied manuscript, but this is treated as an assessability gap rather than a conduct concern.

Flags: 2 declared / 5 total

Reference IntegrityClean

70 of 70 checkable references verified

70 references in manuscript

References not verified automatically are resolved manually within 24 hours.

Post-Publication RecordClean

No retraction or expression of concern found in Crossref (includes Retraction Watch).

Last checked: 17 Oct 2026

Sources: Crossref (incl. Retraction Watch) ✓

Impact Profile

Impact areaHealth · Oral and gastrointestinal · Inflammatory bowel disease
Type of advanceEmpirical
Route to useSuggested
AdvanceAdvances
BeneficiariesSmall
CitationsFWCI 1.8
Policy · patentNot yet traced
ReachedNot reachedNot assessable or unverified
ReadinessControlled
Foundational
Controlled
Piloted
Validated
Implementable
FoundationalImplementable

The primary claim was demonstrated in transgenic mouse models under controlled laboratory conditions, with no human or independent validation reported.

From the paper
“Potential Nrf2 targeted therapies for IBD patients thus may be more beneficial for maintenance of remission, but not for acute flares of the disease.”

The paper names a possible real-world use of its findings, timing Nrf2-targeted therapies in IBD, but does not name who would act on them.

Pathway

Drug developers and gastroenterologists could use these findings to time Nrf2-activating IBD therapies toward remission maintenance rather than acute flares.

Barrier

The evidence comes from constitutive genetic Nrf2 overexpression in mouse colitis models and has not been confirmed in human IBD patients.

Evaluated 12 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3

Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. Personalized redox medicine in inflammatory bowel diseases: an emerging role for HIF-1α and NRF2 as therapeutic targets

    Arno R. Bourgonje, Damian Klóska, Anna Grochot‐Przeczek, et al. · 2023 · Clinical medicine

    Evidence Score
    3.4±0.2
    Reliability
    No concerns
  2. A Protective Role of the NRF2-Keap1 Pathway in Maintaining Intestinal Barrier Function

    Zhiyong Wen, Weihua Liu, Xing Li, et al. · 2019 · Basic medicine

    Primary claim

    NRF2 reduced intestinal mucosal injury by suppressing oxidative stress

    Supported
    Evidence Score
    2.6±0.2
    Reliability
    Caveats
  3. The NRF2/Keap1 pathway as a therapeutic target in inflammatory bowel disease

    Sem Geertsema, Arno R. Bourgonje, Raphael R. Fagundes, et al. · 2023 · Clinical medicine

    Primary claim

    Preclinical evidence supports targeted therapeutic modulation of the NRF2/Keap1 pathway in the gastrointestinal tract, albeit human evidence is scarce.

    Tentative
    Evidence Score
    3.1±0.2
    Reliability
    No concerns

How the rubric works →